EFG activation of patients receiving phenothiazines and chlordiazepoxide.
D000328:Adult; D001007:Anxiety / Q000188:drug therapy; D002540:Cerebral Cortex / Q000187:drug effects*; D002698:Chloralose / Q000494:pharmacology*; D002707:Chlordiazepoxide / Q000494:pharmacology*; D002746:Chlorpromazine / Q000494:pharmacology; D003863:Depression / Q000188:drug therapy; D004569:Electroencephalography; D004827:Epilepsy / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010640:Phenothiazines / Q000009:adverse effects* / Q000494:pharmacology*; D010672:Phenytoin / Q000494:pharmacology; D012559:Schizophrenia / Q000188:drug therapy; D014268:Trifluoperazine / Q000494:pharmacology
D010640:Phenothiazines; D014268:Trifluoperazine; D002698:Chloralose; D010672:Phenytoin; D002707:Chlordiazepoxide; D002746:Chlorpromazine